Diosmin and Hesperidin (MPFF) for Chronic Venous Insufficiency: The Trial Record

Diosmin and hesperidin are citrus-derived flavonoids combined in a micronized purified flavonoid fraction (MPFF) marketed in Europe as Daflon 500 or Detralex. Unlike most flavonoid supplements, MPFF has a substantial trial record for a specific indication — chronic venous insufficiency (CVI) — that has earned guideline recommendations.

Mechanism: vein tone and lymphatic flow

MPFF prolongs noradrenaline-induced venoconstriction, reduces capillary hyperpermeability, and improves lymphatic drainage [1]. In animal microcirculation models it decreases leukocyte adhesion and the inflammatory cascade implicated in vein-wall remodeling. Diosmin is converted in the gut to hesperidin metabolites, and the micronization step substantially improves bioavailability — non-micronized diosmin shows roughly half the systemic exposure [2].

The trial evidence

A 2020 Cochrane review of phlebotonics for venous insufficiency included 66 RCTs and concluded that flavonoids reduce edema and leg pain compared with placebo with moderate certainty [3]. The RELIEF study, a 6-month open-label trial in 5,052 patients, reported clinically meaningful reductions in pain, heaviness, and quality-of-life scores with 1,000 mg/day MPFF [4]. For venous ulcers, MPFF combined with compression therapy improves healing rates and shortens time to closure compared with compression alone [5].

Hemorrhoids — a parallel evidence base

For acute hemorrhoidal flares MPFF 1,500-3,000 mg/day during the first four days, tapering to 1,000 mg/day, reduces bleeding and shortens symptom duration [6]. The American College of Gastroenterology lists flavonoid phlebotonics as an option in mild-to-moderate hemorrhoidal disease, though evidence quality is rated low to moderate.

Practical guidance

The standard dose in trials is 500 mg twice daily of MPFF (90 percent diosmin, 10 percent hesperidin). Effects on subjective symptoms typically emerge within two to four weeks; objective ulcer healing requires three to six months. Side effects are uncommon — mild GI symptoms in roughly 5 percent of users. Generic, non-micronized diosmin products lack the bioavailability of the MPFF formulation studied in trials and may not produce equivalent benefit [7].

The post-sclerotherapy and post-surgical evidence

MPFF has been studied as an adjunct to varicose-vein procedures including sclerotherapy and endovenous laser ablation. Trials report reduced post-procedural bruising, swelling, and pain duration, and somewhat lower rates of post-sclerotherapy pigmentation [8]. Effects on long-term recurrence are not well established.

Putting it in perspective

Among phlebotonics on the global market, MPFF has the deepest evidence base and the only formulation with positive head-to-head comparative work versus other flavonoid preparations. For patients who cannot wear compression stockings consistently, who have residual edema and discomfort despite compression, or who are recovering from venous procedures, MPFF is a defensible add-on with a favorable safety profile. It is not a substitute for compression therapy or for procedural management of significant venous reflux when those are indicated by duplex ultrasound findings.

One thing patients often ask: can dietary citrus consumption substitute for MPFF supplementation? Realistically, no — the diosmin content of even high citrus intake is one to two orders of magnitude below trial doses. Whole-citrus-fruit consumption has its own benefits, but is not pharmacologically equivalent to a 1,000 mg daily standardized phlebotonic regimen.

For patients who want to combine MPFF with horse chestnut seed extract (another commonly used venous tonic), the trial data does not address combinations directly. Most clinicians choose one or the other rather than stack phlebotonics — the marginal additive benefit is unclear and side effects, while uncommon, can add up.